EY Pulse of the MedTech Industry Report 2026: Blockbuster performers and innovation drive record MedTech industry growth

EY reports MedTech revenue reached approximately $650 billion in 2025, up 11%, and $325 billion in the first half of 2026, up 7.1% year over year. Disclosed M&A value rose 160% in the first half of 2026, while total deal value reached roughly $130 billion; financing for the year ended June 30 totaled $63 billion, up 87%. Growth and dealmaking are strong but concentrated among industry leaders, with investor sentiment, margin pressure and trade and supply-chain uncertainty remaining challenges.

Analysis

The investable signal is dispersion, not sector-wide acceleration. Deal value and financing totals appear concentrated, so aggregate growth can coexist with weak outcomes for companies lacking differentiated products or the balance sheet to fund development. Blockbuster M&A may lift acquisition expectations for scarce assets, but it also raises the risk of overpaying and distracts acquirers from integration; announced deal value is not evidence of realized synergies.

AI is more likely to widen the gap between device makers that can prove clinical utility and integrate software into care pathways and those adding features without reimbursement or workflow adoption. FDA authorization alone does not establish recurring revenue. Over 6–18 months, evidence quality, data rights, cybersecurity, and manufacturing execution may matter more than AI labels. ASC and direct-to-patient growth could expand procedure volumes while shifting purchasing toward lower-cost, easier-to-deploy systems—potentially pressuring hospital-oriented pricing and service models.

Near term, the report’s broad figures are not a catalyst for an outright sector long: the headline deal and capital totals may mask concentration, and no company-level valuation, margin, or adoption data are provided. Over 1–3 months, earnings and guidance should reveal whether R&D converts into EBIT expansion or merely higher spend. The contrarian opportunity is selective exposure to proven innovation productivity, rather than buying the whole sector on a recovery narrative.

Key Decisions for Investors

• Consider a market-neutral relative-value basket: long medtech names only after confirming improving EBIT margins alongside productive R&D, against weaker, undifferentiated peers. Screen candidates such as Intuitive Surgical, Boston Scientific, Abbott, and Medtronic; do not assume the report establishes any of them as winners. Enter after the next earnings reports provide company-level evidence. The thesis is relative outperformance if innovation translates into margin gains; it is falsified by margin deterioration or guidance cuts among selected longs.
• Avoid chasing M&A headlines. Track purchase prices, financing mix, integration costs, and post-deal margin guidance; reduce exposure if deal activity is driven by increasingly expensive competition for assets without quantified synergy targets.
• Watch AI claims for commercial proof: procedure adoption, reimbursement, recurring software revenue, and clinical outcomes. Treat regulatory authorization without those indicators as a watch item, not a buy signal; reassess if evidence or guidance shows durable monetization.
• Revisit any sector-wide underweight only if upcoming results show broad—not just leader-driven—organic growth and margin improvement, while trade and supply-chain uncertainty eases. The article provides no valuation or company-level data to justify a price target or immediate directional position.